GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (NAS:VIVO) » Definitions » Beneish M-Score

Meridian Bioscience (Meridian Bioscience) Beneish M-Score : 0.00 (As of Apr. 26, 2024)


View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Meridian Bioscience's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Meridian Bioscience was 0.00. The lowest was 0.00. And the median was 0.00.


Meridian Bioscience Beneish M-Score Historical Data

The historical data trend for Meridian Bioscience's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience Beneish M-Score Chart

Meridian Bioscience Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.43 -2.29 -2.41 -2.04 -2.69

Meridian Bioscience Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.04 -2.52 -2.38 -2.69 -2.69

Competitive Comparison of Meridian Bioscience's Beneish M-Score

For the Diagnostics & Research subindustry, Meridian Bioscience's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meridian Bioscience's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Meridian Bioscience's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Meridian Bioscience's Beneish M-Score falls into.



Meridian Bioscience Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Meridian Bioscience for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8417+0.528 * 1.1187+0.404 * 0.9425+0.892 * 1.0476+0.115 * 0.968
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0838+4.679 * -0.043684-0.327 * 0.7612
=-2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Total Receivables was $47.2 Mil.
Revenue was 65.675 + 67.771 + 111.231 + 88.341 = $333.0 Mil.
Gross Profit was 33.992 + 36.728 + 68.477 + 49.159 = $188.4 Mil.
Total Current Assets was $210.6 Mil.
Total Assets was $463.1 Mil.
Property, Plant and Equipment(Net PPE) was $50.7 Mil.
Depreciation, Depletion and Amortization(DDA) was $16.5 Mil.
Selling, General, & Admin. Expense(SGA) was $89.2 Mil.
Total Current Liabilities was $58.0 Mil.
Long-Term Debt & Capital Lease Obligation was $29.1 Mil.
Net Income was 5.705 + -7.338 + 28.752 + 15.34 = $42.5 Mil.
Non Operating Income was -4.47 + -15.706 + 0.665 + -0.161 = $-19.7 Mil.
Cash Flow from Operations was 1.987 + 14.402 + 30.417 + 35.555 = $82.4 Mil.
Total Receivables was $53.6 Mil.
Revenue was 76.204 + 63.511 + 85.264 + 92.917 = $317.9 Mil.
Gross Profit was 44.717 + 37.111 + 57.772 + 61.548 = $201.1 Mil.
Total Current Assets was $192.8 Mil.
Total Assets was $449.7 Mil.
Property, Plant and Equipment(Net PPE) was $49.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $15.3 Mil.
Selling, General, & Admin. Expense(SGA) was $78.6 Mil.
Total Current Liabilities was $47.2 Mil.
Long-Term Debt & Capital Lease Obligation was $63.9 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(47.235 / 333.018) / (53.568 / 317.896)
=0.141839 / 0.168508
=0.8417

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(201.148 / 317.896) / (188.356 / 333.018)
=0.632748 / 0.565603
=1.1187

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (210.597 + 50.708) / 463.097) / (1 - (192.807 + 49) / 449.722)
=0.435745 / 0.462319
=0.9425

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=333.018 / 317.896
=1.0476

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(15.286 / (15.286 + 49)) / (16.511 / (16.511 + 50.708))
=0.237781 / 0.24563
=0.968

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(89.21 / 333.018) / (78.578 / 317.896)
=0.267883 / 0.247181
=1.0838

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((29.127 + 57.951) / 463.097) / ((63.932 + 47.157) / 449.722)
=0.188034 / 0.247017
=0.7612

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(42.459 - -19.672 - 82.361) / 463.097
=-0.043684

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Meridian Bioscience has a M-score of -2.69 suggests that the company is unlikely to be a manipulator.


Meridian Bioscience Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Meridian Bioscience (Meridian Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
3471 River Hills Drive, Cincinnati, OH, USA, 45244
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.
Executives
Julie Diana Smith officer: Sr VP, Controller, PAO 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John P. Kenny director, officer: Chief Executive Officer 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Andrew S. Kitzmiller officer: EVP & CFO ONE BATESVILLE BLVD., BATESVILLE IN 47006
Bryan T Baldasare officer: Interim CFO & Chief Acctg Off 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Rice John Mccune Jr. director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Bihl Anthony P Iii director 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Tony Serafini-lamanna officer: Executive VP-Diagnostics 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Felicia Williams director C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001
John Mcilwraith director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
David Phillips director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
James M. Anderson director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Dwight E Ellingwood director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lawrence Baldini officer: Exec VP, Operations & IS 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric S. Rasmussen officer: EVP, Bus. Development/Strategy 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lourdes Weltzien officer: EVP, Life Science 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244

Meridian Bioscience (Meridian Bioscience) Headlines

From GuruFocus

Chuck Royce Buys 1, Sells 4 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-03-2022